Slide 1: Waverley Pharma – Corporate Presentation 2023
WAVERLEY PHARMA – CORPORATE PRESENTATION 2023 CONFIDENTIAL 1
Slide 2: Forward-Looking Statements
WAVERLEY PHARMA Forward-Looking Statements Forward Looking Information: Statements contained in this press release products, the ability to protect its intellectual property, dependence that are not statements of historical fact, including, without limitation, upon collaborative partners, changes in
Slide 3: Waverley Pharma Overview
WAVERLEY PHARMA Waverley Pharma Overview A specialty pharma company dedicated to the development and commercialization of safe, effective and affordable therapeutic products Currently focused on the development of its PARP-1 inhibitor project Partnering with contract manufacturing organization
Slide 4: Management
WAVERLEY PHARMA - MANAGEMENT Larry Thiessen, President & CEO 28 years of pharmaceutical experience having worked for Bausch Health Companies Inc. (formerly Biovail Corporation) He led a team of roughly 400 employees and provided overall leadership and strategic direction at the operation Bache
Slide 5: Current Products
WAVERLEY PHARMA – CURRENT PRODUCTS Generic drugs: UK Marketed Generic Drugs: Capecitabine – is a chemotherapy drug used to treat breast cancer, gastric cancer and colorectal cancer. Temozolomide – is a chemotherapy drug used for the treatment of some brain cancers; as a second-line treatment for ast
Slide 6: Current Products: In Development
WAVERLEY PHARMA – CURRENT PRODUCTS In Development: Discovery: PARP-1 Inhibitor – small molecule drug - a new class of anticancer agents targeting DNA repair mechanism PARP inhibitors application treatments: • leukemia • pancreatic cancer • breast cancer • ovarian cancer, etc. Our project goals :
Slide 7: Market Overview
WAVERLEY PHARMA – MARKET OVERVIEW Leading Hospital Oncology Small Molecules The Top 50 Oncology small molecules represent 90% in value and 63% in volume of total Oncology small molecules, among these 36 molecules are not yet genericized given a great opportunity to develop high value & competitive p
Slide 8: UK Market
WAVERLEY PHARMA – UK MARKET Status of MHRA Approvals MHRA Approvals Capecitabine – 150mg and 500mg Temozolomide – 5mg, 20mg, 100mg, 140mg, 180mg and 250mg Bortezomib – 1mg and 3.5mg Pemetrexed – 100mg and 500mg Contracts in process Wholesale Distribution Authorization (WDA) License P
Slide 9: US Market
WAVERLEY PHARMA – US MARKET FDA Approvals Pemetrexed 100mg & 500mg Bortezomib 3.5mg Source: Grandview Research CONFIDENTIAL 9
Slide 10: Key Financial Information
WAVERLEY PHARMA – KEY FINANCIAL INFORMATION Capital Structure as of November 29, 2023 Common shares issued and outstanding: 54,000,000 Share Price: $0.035 Market Cap $1,890,000 CONFIDENTIAL 10